TuHURA Biosciences, Inc./NV 8K

TuHURA Biosciences reported Q2 2026 results, secured a $50 million credit facility with its largest shareholder, and outlined key upcoming clinical and regulatory milestones for its oncology pipeline.

On August 14, 2026, TuHURA Biosciences, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a corporate update, highlighting the filing of an IND for its VISTA-inhibiting antibody TBS-2025 in AML and other blood cancers, the April 2026 establishment of a $50 million term credit facility and royalty transaction with its largest shareholder extending expected cash runway into 2028, and outlining anticipated development milestones across its IFx-2.0, TBS-2025, and MDSC inhibitor programs, while disclosing quarter-end cash of $1.0 million, increased R&D and G&A expenses, and net operating cash outflows partially offset by financing inflows under its ATM and Parkview credit facilities.

Filing Facts

CIK

1498382

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-350425

Alert Tier

6